NEUP (Neuphoria Therapeutics) FCF Margin %: 0.00% (As of Mar. 2026)

What is Neuphoria Therapeutics FCF Margin %?

Neuphoria Therapeutics NEUP +5.18% 32 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates NEUP with a GF Score™ of 32/100. The stock has 1 warning sign investors should review. Among 959 Biotechnology companies, Neuphoria Therapeutics ranks better than 99.9% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Neuphoria Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-3.34 Mil. Neuphoria Therapeutics's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Neuphoria Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Neuphoria Therapeutics's current FCF Yield % is -69.45%.

The historical rank and industry rank for Neuphoria Therapeutics's FCF Margin % or its related term are showing as below:

NEUP' s FCF Margin % Range Over the Past 10 Years
Min: -8396.88 Med: -410.08 Max: 131938.46
Current: 131938.46

During the past 13 years, the highest FCF Margin % of Neuphoria Therapeutics was 131938.46%. The lowest was -8396.88%. And the median was -410.08%.

NEUP's FCF Margin % is ranked better than
99.9% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs NEUP: 131938.46

Neuphoria Therapeutics FCF Margin % Related Terms

Neuphoria Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Neuphoria Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Neuphoria Therapeutics FCF Margin % Chart

Neuphoria Therapeutics Annual Data

Trend

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Jun25

FCF Margin %

Get a 7-Day Free Trial

0.00

-8,269.06

0.00

0.49

Neuphoria Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
FCF Margin %	Get a 7-Day Free Trial															76.35	27,576.92	0.00	0.00	0.00

NEUP vs CRVO, IGC, SNSE: FCF Margin % Comparison

For the Biotechnology subindustry, Neuphoria Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Neuphoria Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Neuphoria Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Neuphoria Therapeutics's FCF Margin % falls into.

Save Embed

32GF Score

Neuphoria Therapeutics Inc NEUP

FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Neuphoria Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Neuphoria Therapeutics's FCF Margin for the fiscal year that ended in Jun. 2025 is calculated as

FCF Margin	=	Free Cash Flow (A: Jun. 2025 )	/	Revenue (A: Jun. 2025 )
	=	0.077	/	15.649
	=	0.49 %

Neuphoria Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2026 )	/	Revenue (Q: Mar. 2026 )
	=	-3.336	/	0
	=	%

Frequently Asked Questions Learn more about FCF Margin % →

What does a FCF Margin % of 0.00% mean?

Neuphoria Therapeutics (NEUP) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neuphoria Therapeutics and its competitors. According to the industry distribution chart, Neuphoria Therapeutics ranks #1 out of 959 companies in the Biotechnology industry, placing it in the top 0.099999999999994%.

Is Neuphoria Therapeutics' FCF Margin % too high?

Neuphoria Therapeutics' current FCF Margin % is 0.00%. Based on the distribution chart, Neuphoria Therapeutics ranks #1 out of 959 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Neuphoria Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.

How does Neuphoria Therapeutics' FCF Margin % compare to CRVO and IGC?

According to the Biotechnology industry distribution chart, Neuphoria Therapeutics ranks #1 out of 959 companies for FCF Margin %. This places Neuphoria Therapeutics in the top 0% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good FCF Margin % for a Biotechnology company?

A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high FCF Margin % mean?

A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Neuphoria Therapeutics and its competitors. Neuphoria Therapeutics's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Neuphoria Therapeutics stock overvalued right now?

Neuphoria Therapeutics (NEUP) has a current FCF Margin % of 0.00%. The current FCF Margin % is 0.00%. Neuphoria Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is FCF Margin % calculated?

FCF Margin % is calculated from a company's financial statements. For Neuphoria Therapeutics (NEUP), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Neuphoria Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies CRVO IGC SNSE CELU DYAI KYNB SNTI NRSN SER LSTA VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Address 100 Summit Drive, Burlington, MA, USA, 01803

Website https://www.neuphoriatx.com

Neuphoria Therapeutics Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder. The Company operates through a single operating and reportable segment focused on the discovery and development of allosteric ion channel modulators designed to transform the lives of patients suffering from serious central nervous system (CNS) disorders with high unmet medical need.

32GF Score

Get the complete analysis for NEUP

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.53

Price

View NEUP Analysis

See FCF Margin % data for all stocks →